112 related articles for article (PubMed ID: 7826209)
1. Biological and pharmacokinetic properties of a novel immunoglobulin-CD4 fusion protein.
Lyczak JB; Morrison SL
Arch Virol; 1994; 139(1-2):189-96. PubMed ID: 7826209
[TBL] [Abstract][Full Text] [Related]
2. Antiviral effects of different CD4-immunoglobulin constructs against HIV-1 and SIV: immunological characterization, pharmacokinetic data and in vivo experiments.
Langner KD; Niedrig M; Fultz P; Anderson D; Reiner G; Repke H; Gelderblom H; Seed B; Hilfenhaus J; Zettlmeissl G
Arch Virol; 1993; 130(1-2):157-70. PubMed ID: 8503781
[TBL] [Abstract][Full Text] [Related]
3. Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1.
Chen W; Bardhi A; Feng Y; Wang Y; Qi Q; Li W; Zhu Z; Dyba MA; Ying T; Jiang S; Goldstein H; Dimitrov DS
MAbs; 2016; 8(4):761-74. PubMed ID: 26963639
[TBL] [Abstract][Full Text] [Related]
4. An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques.
Shubin Z; Li W; Poonia B; Ferrari G; LaBranche C; Montefiori D; Zhu X; Pauza CD
Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28404572
[TBL] [Abstract][Full Text] [Related]
5. Engineering and functional evaluation of a single-chain antibody against HIV-1 external glycoprotein gp120.
Wang HW; Cole D; Jiang WZ; Jin HT; Fu N; Chen ZL; Jin NY
Clin Exp Immunol; 2005 Jul; 141(1):72-80. PubMed ID: 15958072
[TBL] [Abstract][Full Text] [Related]
6. Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life.
Zuckier LS; Chang CJ; Scharff MD; Morrison SL
Cancer Res; 1998 Sep; 58(17):3905-8. PubMed ID: 9731501
[TBL] [Abstract][Full Text] [Related]
7. An immunoglobulin fusion protein based on the gp120-CD4 receptor complex potently inhibits human immunodeficiency virus type 1 in vitro.
Vu JR; Fouts T; Bobb K; Burns J; McDermott B; Israel DI; Godfrey K; DeVico A
AIDS Res Hum Retroviruses; 2006 Jun; 22(6):477-90. PubMed ID: 16796521
[TBL] [Abstract][Full Text] [Related]
8. Enzymatic cleavage of a CD4 immunoadhesin generates crystallizable, biologically active Fd-like fragments.
Chamow SM; Peers DH; Byrn RA; Mulkerrin MG; Harris RJ; Wang WC; Bjorkman PJ; Capon DJ; Ashkenazi A
Biochemistry; 1990 Oct; 29(42):9885-91. PubMed ID: 2125484
[TBL] [Abstract][Full Text] [Related]
9. Expression and characterization of human CD4:immunoglobulin fusion proteins.
Zettlmeissl G; Gregersen JP; Duport JM; Mehdi S; Reiner G; Seed B
DNA Cell Biol; 1990 Jun; 9(5):347-53. PubMed ID: 2196903
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 neutralization by chimeric CD4-CG10 polypeptides fused to human IgG1.
Meyuhas R; Noy H; Montefiori DC; Denisova G; Gershoni JM; Gross G
Mol Immunol; 2005 May; 42(9):1099-109. PubMed ID: 15829299
[TBL] [Abstract][Full Text] [Related]
11. Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding.
Harrop HA; Coombe DR; Rider CC
AIDS; 1994 Feb; 8(2):183-92. PubMed ID: 8043225
[TBL] [Abstract][Full Text] [Related]
12. Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules.
Traunecker A; Schneider J; Kiefer H; Karjalainen K
Nature; 1989 May; 339(6219):68-70. PubMed ID: 2541344
[TBL] [Abstract][Full Text] [Related]
13. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulins.
He Y; D'Agostino P; Pinter A
Vaccine; 2003 Oct; 21(27-30):4421-9. PubMed ID: 14505925
[TBL] [Abstract][Full Text] [Related]
15. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
16. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor.
Dey B; Del Castillo CS; Berger EA
J Virol; 2003 Mar; 77(5):2859-65. PubMed ID: 12584309
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates.
Kessler JA; McKenna PM; Emini EA; Chan CP; Patel MD; Gupta SK; Mark GE; Barbas CF; Burton DR; Conley AJ
AIDS Res Hum Retroviruses; 1997 May; 13(7):575-82. PubMed ID: 9135875
[TBL] [Abstract][Full Text] [Related]
18. Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding.
Celada F; Cambiaggi C; Maccari J; Burastero S; Gregory T; Patzer E; Porter J; McDanal C; Matthews T
J Exp Med; 1990 Oct; 172(4):1143-50. PubMed ID: 2212945
[TBL] [Abstract][Full Text] [Related]
19. Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody.
Chen SY; Khouri Y; Bagley J; Marasco WA
Proc Natl Acad Sci U S A; 1994 Jun; 91(13):5932-6. PubMed ID: 8016092
[TBL] [Abstract][Full Text] [Related]
20. Long-term maintenance of gp120-specific immune responses by genetic vaccination with the HIV-1 envelope genes linked to the gene encoding Flt-3 ligand.
Sailaja G; Husain S; Nayak BP; Jabbar AM
J Immunol; 2003 Mar; 170(5):2496-507. PubMed ID: 12594275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
